Core Laboratories Inc. (CLB) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2026. Core Laboratories Inc. operates in two segments: Reservoir Description (laboratory analysis of rock and fluids) and Production Enhancement (well completion and diagnostic services). The company serves the global oil and gas industry, with significant exposure to international markets including the Middle East, Russia, and the U.S. onshore basins.
Key Financial Metrics (Three Months Ended June 30, 2026)
| Metric | Q2 2026 | Q2 2025 | Y/Y Change |
|---|---|---|---|
| Total Revenue | $124.6 million | $130.2 million | (4)% |
| Operating Income | $9.2 million | $15.3 million | (40)% |
| Net Income (Attributable to CLB) | $6.0 million | $10.6 million | (44)% |
| Diluted EPS | $0.13 | $0.22 | (41)% |
| Cash and Equivalents | $22.7 million | $31.2 million (Q2 2025) | N/A |
| Long-Term Debt (Net) | $113.9 million | $110.3 million (Dec 2025) | +3.3% |
| Free Cash Flow (6 Months) | $3.6 million | $14.3 million | (75)% |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 4% year-over-year. Reservoir Description revenue fell 9% due to geopolitical conflicts in the Middle East and Russia/Ukraine, which disrupted crude oil trading and reduced demand for laboratory assays. Production Enhancement revenue increased 5% driven by U.S. onshore activity and well diagnostic services.
- Margin Compression: Operating margins declined from 12% in Q2 2025 to 7% in Q2 2026. This was driven by fixed cost structures in international regions where revenue dropped, higher inflationary costs for laboratory supplies, and the absence of a $2.5 million insurance recovery gain recorded in the prior year (Aberdeen fire).
- Debt Restructuring: In January 2026, the company retired $45.0 million of Senior Notes Series A using proceeds from a $50.0 million Delayed Draw Term Loan (DDTL). This increased variable interest rate exposure.
- Share Repurchases: The company repurchased 214,712 shares for approximately $2.7 million in Q2 2026.
Outlook, Risks, and Management Commentary
- Geopolitical Risks: Management highlights significant volatility due to the escalation of conflict between the U.S./Israel and Iran. Disruptions in the Strait of Hormuz have reduced global crude cargo movement by 15-20%, directly impacting demand for assay services. Sanctions on Russia continue to restrict operations.
- Market Dynamics: Clients are prioritizing capital management and return on invested capital over production growth. While large-scale international projects are expected to remain resilient, smaller-scale U.S. onshore projects are sensitive to crude price volatility.
- Liquidity: The company maintains a $150.0 million credit facility with approximately $85.6 million available. It is in compliance with all covenants, with an interest coverage ratio of 6.53 and a leverage ratio of 1.30.
- Unusual Items: Q2 2025 included significant insurance recoveries ($2.5 million) from a 2024 fire in Aberdeen, UK, which are not recurring. Q2 2026 included a partial insurance settlement of $0.2 million for storm damage in Malta.
Investor Verification Checklist
- Geopolitical Exposure: Verify the specific percentage of revenue at risk from the Middle East and Russia/Ukraine regions given the ongoing conflict.
- Cost Structure Rigidity: Assess the ability to reduce fixed costs in international regions where revenue has declined due to sanctions and conflict.
- Debt Servicing: Monitor the impact of the new variable-rate Delayed Draw Term Loan on interest expense as rates fluctuate.
- Insurance Recoveries: Confirm the finality of the Aberdeen fire settlement and the status of the Malta storm damage claim to understand the true recurring operating income.
- Free Cash Flow: Review the sustainability of free cash flow generation given the 75% year-over-year decline in the first half of 2026.